Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies - Full Text View

Purpose

This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.

Condition	Intervention	Phase
Acute Lymphoid Leukemia Acute Myeloid Leukemia Anemia, Refractory, With Excess of Blasts Solid Tumors	Drug: brentuximab vedotin	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment
Official Title:	A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Resource links provided by NLM:

Genetics Home Reference related topics: core binding factor acute myeloid leukemia cytogenetically normal acute myeloid leukemia familial acute myeloid leukemia with mutated CEBPA

Drug Information available for: Brentuximab vedotin

Genetic and Rare Diseases Information Center resources: Myeloid Leukemia Acute Myeloid Leukemia Acute Non Lymphoblastic Leukemia Myelodysplastic Syndromes Acute Lymphoblastic Leukemia Lymphosarcoma

U.S. FDA Resources

Further study details as provided by Seattle Genetics, Inc.:

Primary Outcome Measures:

Objective Response Rate (ORR) by Investigator [ Time Frame: Up to approximately 3 years ]
Percentage of participants who achieved a best response of complete response/remission (CR), CR without hematologic recovery (CRi; leukemia only), or partial remission (PR) per the applicable response criteria. Response criteria for solid tumors (by radiographic tumor imaging) per Response Evaluation Criteria for Solid Tumors (RECIST) 1.1 (Eisenhauer 2009); response criteria for leukemia (by peripheral blood and bone marrow aspirate or biopsy) per International Working Group (Cheson 2003).

Secondary Outcome Measures:

Complete Remission (CR) Rate by Investigator [ Time Frame: Up to approximately 3 years ]
Percentage of participants who achieved a best response of CR per the applicable response criteria. Response criteria for solid tumors (by radiographic tumor imaging) per Response Evaluation Criteria for Solid Tumors (RECIST) 1.1 (Eisenhauer 2009); response criteria for leukemia (by peripheral blood and bone marrow aspirate or biopsy) per International Working Group (Cheson 2003).
Duration of Objective Response by Kaplan-Meier Analysis [ Time Frame: Up to approximately 2 years ]
Duration of objective response (CR [+CRi; leukemia] + PR), defined as time of initial response until disease progression or death. Response criteria for solid tumors (by radiographic tumor imaging) per Response Evaluation Criteria for Solid Tumors (RECIST) 1.1 (Eisenhauer 2009); response criteria for leukemia (by peripheral blood and bone marrow aspirate or biopsy) per International Working Group (Cheson 2003).
Duration of Complete Response by Kaplan-Meier Analysis [ Time Frame: Up to approximately 2 years ]
Duration of CR, defined as time of initial response until disease progression or death. Response criteria for solid tumors (by radiographic tumor imaging) per Response Evaluation Criteria for Solid Tumors (RECIST) 1.1 (Eisenhauer 2009); response criteria for leukemia (by peripheral blood and bone marrow aspirate or biopsy) per International Working Group (Cheson 2003).
Progression-Free Survival by Kaplan-Meier Analysis [ Time Frame: Up to approximately 2 years ]
Progression-free survival, defined as time from start of study treatment to disease progression per investigator or death due to any cause
Adverse Events by Severity, Seriousness, and Relationship to Treatment [ Time Frame: Up to approximately 3 years ]
Counts of participants who had treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose on Study SGN35-013). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life-threatening/disabling, 5=fatal). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.
Laboratory Abnormalities >/= Grade 3 [ Time Frame: Up to approximately 3 years ]
Counts of study participants with post-baseline laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 4.03. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category
Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Concentration at End of Infusion (Ceoi) [ Time Frame: Up to approximately 3 years ]
Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Trough Concentration (Ctrough) [ Time Frame: Up to approximately 3 years ]
Maximum Concentration (Cmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE) [ Time Frame: Up to approximately 3 years ]
Brentuximab Vedotin Monomethyl Auristatin E (MMAE) Trough Concentration (Ctrough) [ Time Frame: Up to approximately 3 years ]
Incidence of Anti-therapeutic Antibodies (ATA) [ Time Frame: Up to approximately 3 years ]
Counts of participants with post-baseline anti-brentuximab vedotin antibodies. Persistently positive is defined as confirmed ATA in more than 2 post-baseline samples and transiently positive is defined as confirmed ATA in 1 or 2 post-baseline samples.


Enrollment:	84
Study Start Date:	October 2011
Study Completion Date:	December 2014
Primary Completion Date:	December 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Brentuximab vedotin 1.8 mg/kg Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion	Drug: brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion Other Name: Adcetris; SGN-35
Experimental: Brentuximab vedotin 2.4 mg/kg Brentuximab vedotin 2.4 mg/kg every 3 weeks by IV infusion	Drug: brentuximab vedotin 2.4 mg/kg every 3 weeks by intravenous (IV) infusion Other Name: Adcetris; SGN-35
Experimental: Brentuximab vedotin 1.2 mg/kg Brentuximab vedotin 1.2 mg/kg weekly, 3 out of 4 weeks, by IV infusion	Drug: brentuximab vedotin 1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion Other Name: Adcetris; SGN-35

Eligibility


Ages Eligible for Study:	6 Years and older (Child, Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Histologically-confirmed by central review CD30-positive nonlymphomatous malignancy
Have failed, refused, or have been deemed ineligible for standard therapy
Measurable disease
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 or a Karnofsky or Lansky Performance Status score greater than or equal to 70

Exclusion Criteria:

Primary diagnosis of lymphoma or central nervous system (CNS) malignancy
History of another primary invasive malignancy that has not been definitively treated or in remission for at least 3 years
Evidence of active cerebral/meningeal disease

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01461538

Show 29 Study Locations

Sponsors and Collaborators

Seattle Genetics, Inc.

Investigators


Study Director:	Neil Josephson, MD	Seattle Genetics, Inc.

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Borate U, Mehta A, Reddy V, Tsai M, Josephson N, Schnadig I. Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin. Leuk Res. 2016 May;44:25-31. doi: 10.1016/j.leukres.2016.02.010. Epub 2016 Feb 27.

Giannatempo P, Paolini B, Miceli R, Raggi D, Nicolai N, Farè E, Catanzaro M, Biasoni D, Torelli T, Stagni S, Piva L, Mariani L, Salvioni R, Colecchia M, Gianni AM, Necchi A. Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment. J Urol. 2013 Nov;190(5):1919-24. doi: 10.1016/j.juro.2013.04.057. Epub 2013 Apr 25.


Responsible Party:	Seattle Genetics, Inc.
ClinicalTrials.gov Identifier:	NCT01461538 History of Changes
Other Study ID Numbers:	SGN35-013
Study First Received:	October 24, 2011
Results First Received:	December 18, 2015
Last Updated:	February 5, 2016

Keywords provided by Seattle Genetics, Inc.:


Acute Lymphoid Leukemia Myelodysplastic Syndrome Acute Myeloid Leukemia Solid Tumors Anemia, Refractory, with Excess of Blasts Antibodies, Monoclonal	Antibody-Drug Conjugate Antigens, CD30 Drug Therapy Hematologic Diseases Immunotherapy Monomethyl Auristatin E

Additional relevant MeSH terms:


Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Leukemia, Lymphoid Precursor Cell Lymphoblastic Leukemia-Lymphoma Anemia, Refractory Anemia, Refractory, with Excess of Blasts Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases	Immunoproliferative Disorders Immune System Diseases Anemia Hematologic Diseases Myelodysplastic Syndromes Bone Marrow Diseases Antibodies Antibodies, Monoclonal Immunologic Factors Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 21, 2017